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Assessing baseline comparability in randomised trialsIntroduction
Randomisation is used to allocate participants to groups (eg, an
intervention group and a control group) in clinical trials because
this process tends to generate groups with similar characteristics.1
When the groups have similar characteristics at baseline, and only
one of the groups then receives an intervention, the difference in
outcomes between the groups can therefore be attributed to that
intervention. Occasionally, randomised trials produce groups that
are not comparable at baseline, which can bias estimates of the
effect of the intervention.
What can disrupt baseline comparability?
Small sample sizes
Small trials are prone to larger baseline imbalances [4_TD$DIFF] than large
trials, due to random chance[2_TD$DIFF]. Unfortunately, many physiotherapy
trials are small. In a representative sample of 100 randomised trials
published in 2014 and indexed on the Physiotherapy Evidence
Database (PEDro) website, half of the trials had 40 participants or
fewer.
Non-concealment of the random allocation list
In some trials, a list of randomly ordered allocations is given to
investigators who use it to allocate each participant they enrol to a
group. For reasons detailed in an earlier Research Note,2 these
investigators may wish that certain participants are allocated to a
particular group. An investigator who knows the upcoming group
on a random allocation list can subtly inﬂuence whether a patient
is allocated to a particular group. For example, the investigatormay
change the order in which prospective participants are
approached, or give more emphasis to the positive or negative
aspects of participating in the trial with particular people. This
inﬂuence can disrupt the baseline comparability of the groups.
Although this scenario is easily prevented by concealing the
random allocation list from the enrolling investigators, most trials
of physiotherapy [5_TD$DIFF]interventions still do not report doing so.3
Quasi-random allocation
Instead of truly random processes, like a coin toss, some trials
use a quasi-random process to allocate participants to groups. For
example, participants may be allocated to groups based on
whether their birthdate or hospital ID number is odd or even.
Such processes could essentially work like randomisation, except
that concealing the person’s upcoming allocation would be more
difﬁcult. Some other processes that are also sometimes called
quasi-randomprocesses are even less ideal. For example, imagine a
trial of a new intervention for acute management of knee injuries,
where participants are allocated to groups based on the day of the
week on which they present to a hospital emergency department
for treatment. As well as being impossible to conceal, allocation byhttp://dx.doi.org/10.1016/j.jphys.2015.07.005
1836-9553/ 2015 Australian Physiotherapy Association. Published by Elsevier B.V. Alday of the week may be inﬂuenced by participant differences (eg,
demographic characteristics, injury severity, or usual care re-
ceived) depending on the day of presentation. Therefore, quasi-
random allocation may induce systematic differences between
groups at baseline.
Chance
Even a large trial with concealed allocation and true
randomisation may rarely generate groups that have important
imbalance in some characteristics. Therefore, baseline compara-
bility should always be considered when writing or reading the
trial report.
What should be considered when assessing baseline
comparability?
Some participants in a clinical trial may have characteristics
that are prognostic for the disease outcome. For example, spine
asymmetry has been shown to be a risk factor for the ﬁrst episode
of low back pain in children.4,5 Conversely, body mass index has
been examined in ﬁve prospective observational cohorts of
children, but it was not found to be predictive of the ﬁrst episode
of low back pain in any of the ﬁve studies.5–9 In a controlled trial of
an intervention intended to prevent the onset of low back pain in
children, it may be of more concern if there was a substantial
baseline between-group difference in the proportion of children
with spine asymmetry than if there was a substantial baseline
between-group difference for body mass index. Other participant
characteristics that may have the potential to inﬂuence the
outcome if they differ substantially at baseline are measures of the
severity of the disease or measures that will be taken again at the
end of the trial to test the effect of the intervention.
For any of these differences, there is no objective test to
determine when a difference will inﬂuence the outcomes of the
trial. Instead, clinical judgement should be used to consider
whether the difference is substantial enough to be likely to have
inﬂuenced the outcome.
Even if a substantial baseline imbalance in an important
prognostic factor exists, this is less of a concern if the trial had a
large sample size and used a truly random process that was
protected with concealed allocation. This is because some
unmeasured baseline characteristics may be equally important
prognostically, and it might be anticipated that randomisation
would even out the inﬂuence of the various imbalances (ie, those
measured and those unmeasured) so that overall prognosis might
be similar between the groups.
Why aren’t statistical tests recommended to assess baseline
comparability?
Statistical tests are used at the end of the trial to determine how
likely it is that the difference in outcomes between the groups has
occurred by chance. If the difference between the groups is veryl rights reserved.
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less than a 1-in-20 chance, which is often written as p< 0.05), then
that intervention is interpreted as causing the difference. The
between-group difference is then interpreted as the average effect
of the intervention in that population. In some journals, it is still
common to see these statistical tests also applied to the baseline
data in order to assess the comparability of the groups before
treatment. When statistical tests are conducted to assess baseline
comparability, they can be reported in several ways: in the table
that summarises the baseline characteristics of the groups (as p-
values in a column or footnote), or as a statement in the main text
about which baseline measures were statistically signiﬁcantly
different. However, the use of statistical tests to assess baseline
comparability is illogical, as noted by Altman in 1985:
. . . performing a signiﬁcance test to compare baseline variables is
to assess the probability of something having occurred by chance
when we know that it did occur by chance. Such a procedure is
clearly absurd.10
What Altman is referring to is the fact that the participants at
baseline have not yet undergone treatment, so any baseline
differences must be due to chance; therefore, it does not make
sense to conduct a statistical test to determine the likelihood that a
difference occurred by chance because we already know it did
occur by chance. In 1994, Senn wrote:
I suspect that the practice has originated through confused and
false analogies with signiﬁcance and hypothesis tests in general.11
That is, some researchers forget that statistical tests assess
whether a between-group difference in outcome is likely to have
occurred by chance, and instead interpret statistical tests as being a
measure of how big or important the between-group difference is.
When misinterpreted in this way, statistical tests at baseline
become potentially misleading, because irrelevant or clinically
trivial differences that are too small to inﬂuence the outcome can
sometimes be highly statistically signiﬁcant. Conversely, large and
relevant baseline differences can sometimes be statistically non-
signiﬁcant, especially in small trials.
Statisticians and clinical research methodologists have main-
tained that baseline signiﬁcance testing should not be performed,
with Austin noting in 2010:
With few exceptions, the statistical literature is uniform in its
agreement on the inappropriateness of using hypothesis testing to
compare the distribution of baseline covariates between treated
and untreated subjects in randomised controlled trials.12
In the same sample of 100 trials from the PEDro website
mentioned above, 63 of the trials reported baseline statistical tests.
The recommendation against baseline signiﬁcance testing has
now been included as Item 15 in thewidely endorsed Consolidated
Standards of Reporting Trials (CONSORT) Statement:
Such hypothesis testing is superﬂuous and can mislead investiga-
tors and their readers. Rather, comparisons at baseline should be
based on consideration of the prognostic strength of the variables
measured and the size of any chance imbalances that have
occurred.13
In other words, readers need only to look at the table of baseline
comparisons and to use their clinical judgement to decide if any of
the differences are substantial enough to have inﬂuenced the
outcome. Despite this recommendation in the CONSORT State-
ment, baseline signiﬁcance tests are still reported in many
randomised trials published in journals that claim to enforce the
CONSORT Statement.14–17
What if the size of the groups is uneven?
For true baseline comparability, some people believe that the
size of the randomly allocated groups must be similar or evenexactly equal. (In an attempt to ensure similar-sized groups, some
researchers even generate a random allocation list that is
comprised of smaller blocks of allocations, where each block
has an equal number of experimental and control allocations that
are randomly ordered within the block. Regardless of the number
of participants enrolled when recruitment stops, blocked rando-
misation ensures that the ﬁnal groups will be similar in size.)
However, randomly allocated groups do not need to be the same
size for true baseline comparability. If the characteristics of the
participants are comparable, any differences in group sizes do not
bias the result or reduce the statistical power of the study. In fact,
in some trials, random allocation is weighted to intentionally
make one group bigger.18 For example, in a trial comparing real
versus sham transcutaneousmagnetic stimulation of the cerebel-
lum after posterior stroke, the investigators used a randomisation
method that produced twice as many allocations to the real
stimulation.19 This was done to generate more data about
tolerability and adverse events that occur with the magnetic
stimulation. If even greater imbalance is used, then the statistical
power of the studywill start to decrease;20 therefore, the required
sample size should [6_TD$DIFF] be calculated to allow for this.21 However, this
degree of imbalance between group sizes is extremely unlikely
with simple random allocation, so investigators need not use
procedures such as blocked allocation to ensure equal group sizes
and need not be concernedwith the differences in group sizes that
occur by chance. Use of uneven randomisation appears to be very
uncommon in trials of physical interventions.18 However,
physiotherapy researchers could consider using it for several
reasons: to increase the amount of data on potentially rare
adverse events (as discussed above); to reduce the cost of a trial
(by favouring allocation to the least expensive group); or to ensure
a sufﬁcient ﬁnal sample size in a group anticipated to have a high
rate of discontinuation of therapy (at least for a per-protocol
analysis).18
Can anything be done to increase baseline comparability?
Although simple randomisation is generally sufﬁcient to
achieve baseline comparability, researchers can enforce a degree
of comparability on a particular factor with stratiﬁed randomisa-
tion.1 For example, in a controlled trial of a program to stimulate
physical activity in children with cerebral palsy,22 randomisation
was stratiﬁed to ensure that the proportion of participants with a
GrossMotor Function Classiﬁcation System level I versus level II/III
was similar in each group. An alternative example is seen in a
multi-centre randomised trial investigating treatment for arm
motor deﬁcits after stroke.23 Here, the factor that was stratiﬁed
during randomisation was the site of enrolment, to ensure that
each site had a similar proportion of participants in the
experimental and control groups. There are several methods of
stratiﬁcation, which can differ in the degree of comparability they
ensure.1,24 Stratiﬁcation for more than one factor is also possible,
but issues with feasibility and complexity increase rapidly as each
additional factor is added.1
Conclusion
True randomisation is generally enough to ensure sufﬁcient
baseline comparability between groups in a clinical trial, especially
when combined with concealed allocation and a large sample size.
Nevertheless, authors of a report of a randomised trial should
include a table of baseline characteristics of participants in each
group, without between-group statistical comparisons. The
report’s authors and readers should use this table to decide
whether any characteristics were imbalanced enough to have
inﬂuenced the outcomes of the study.
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